Key result
Elevated ADMA links to diabetic microvascular complication progression via endothelial dysfunction, oxidative stress, and inflammation.
This review highlights the role of asymmetric dimethylarginine (ADMA) in the pathogenesis of diabetic microvascular complications.
ADMA may aid risk stratification in diabetic microvascular disease; leaves open whether targeting it improves outcomes in trials.
Microvascular complications are the leading causes of acquired blindness, end-stage renal failure, and varieties of neuropathy associated with diabetes. Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, is involved in endothelial dysfunction, oxidative stress, and inflammation associated with the progression of diabetic microvascular complications. Elevated ADMA has been detected in experimental animals and patients with diabetic microangiopathy like retinopathy, nephropathy, and neuropathy. In the review, we focus on the role of ADMA in the pathobiology of major microvascular complications of diabetes.
No takes yet. Share an insight, caveat, or question.
Du et al. (2016) conducted a review in Diabetic microvascular complications. Asymmetric dimethylarginine (ADMA) was evaluated. Elevated asymmetric dimethylarginine (ADMA) is involved in endothelial dysfunction, oxidative stress, and inflammation associated with the progression of diabetic microvascular complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: